메뉴 건너뛰기




Volumn 23, Issue 3, 2010, Pages 287-292

New drug therapies for multiple sclerosis

Author keywords

Autoimmune disease; Demyelination; Experimental autoimmune encephalomyelitis; Inflammatory disease; Multiple sclerosis

Indexed keywords

4 AMINOPYRIDINE; ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; BETA1 INTERFERON; BHT 3009; CALPASTATIN; CHAPERONIN; DACLIZUMAB; DNA VACCINE; FINGOLIMOD; FUMARIC ACID; GEMSP; GLATIRAMER; HERBACEOUS AGENT; IMMUNOGLOBULIN; LAQUINIMOD; LITHIUM; MEVINOLIN; MS 14; PACLITAXEL; PHENYTOIN; PROBIOTIC AGENT; PROTIRAMER; RABEXIMOD; RIBAVIRIN; RITUXIMAB; ROLIPRAM; SITOSTEROL; UNCLASSIFIED DRUG; USTEKINUMAB;

EID: 77951975522     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833960f6     Document Type: Review
Times cited : (22)

References (25)
  • 1
    • 65249138318 scopus 로고    scopus 로고
    • Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    • Bibiana B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66:483-489.
    • (2009) Arch Neurol , vol.66 , pp. 483-489
    • Bibiana, B.1    Howard, T.2    Packer, A.N.3
  • 2
    • 61849150375 scopus 로고    scopus 로고
    • Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis
    • Broadley SA, Vanags D, Williams B, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009; 15:329-336.
    • (2009) Mult Scler , vol.15 , pp. 329-336
    • Broadley, S.A.1    Vanags, D.2    Williams, B.3
  • 3
    • 60649090430 scopus 로고    scopus 로고
    • Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial
    • Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373:732-738.
    • (2009) Lancet , vol.373 , pp. 732-738
    • Goodman, A.D.1    Brown, T.R.2    Krupp, L.B.3
  • 4
    • 70450220588 scopus 로고    scopus 로고
    • A new drug candidate (GEMSP) for multiple sclerosis
    • Mangas A, Coveñas R, Bodet D, et al. A new drug candidate (GEMSP) for multiple sclerosis. Curr Med Chem 2009; 16:3203-3214.
    • (2009) Curr Med Chem , vol.16 , pp. 3203-3214
    • Mangas, A.1    Coveñas, R.2    Bodet, D.3
  • 5
    • 47949096771 scopus 로고    scopus 로고
    • Lithium prevents and ameliorates experimental autoimmune encephalomyelitis
    • De Sarno P, Axtell RC, Raman C, et al. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008; 181:338-345.
    • (2008) J Immunol , vol.181 , pp. 338-345
    • De Sarno, P.1    Axtell, R.C.2    Raman, C.3
  • 6
    • 70349646802 scopus 로고    scopus 로고
    • Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A
    • Crume KP, O'Sullivan D, Miller JH, et al. Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J Leukoc Biol 2009; 86:949-958.
    • (2009) J Leukoc Biol , vol.86 , pp. 949-958
    • Crume, K.P.1    O'Sullivan, D.2    Miller, J.H.3
  • 7
    • 64849084182 scopus 로고    scopus 로고
    • Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-Cell receptor ligand
    • Sinha S, Subramanian S, Miller L, et al. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-Cell receptor ligand. J Neurosci 2009; 29:3816-3823.
    • (2009) J Neurosci , vol.29 , pp. 3816-3823
    • Sinha, S.1    Subramanian, S.2    Miller, L.3
  • 8
    • 50149085078 scopus 로고    scopus 로고
    • An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis
    • Tafreshi1 AP, Ahmadi A, Ghaffarpur M, et al. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. Phytother Res 2008; 22:1083-1086.
    • (2008) Phytother Res , vol.22 , pp. 1083-1086
    • Tafreshi, A.P.1    Ahmadi, A.2    Ghaffarpur, M.3
  • 9
    • 53049089734 scopus 로고    scopus 로고
    • Phenytoin protects central axons in experimental autoimmune encephalomyelitis
    • Black JA, Waxman SG. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci 2008; 274:57-63.
    • (2008) J Neurol Sci , vol.274 , pp. 57-63
    • Black, J.A.1    Waxman, S.G.2
  • 10
    • 58349110928 scopus 로고    scopus 로고
    • The novel small molecule drug rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders
    • Hultqvist M, Nandakumar KS, Björklund U, Holmdahl R. The novel small molecule drug rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis 2009; 68:130-135.
    • (2009) Ann Rheum Dis , vol.68 , pp. 130-135
    • Hultqvist, M.1    Nandakumar, K.S.2    Björklund, U.3    Holmdahl, R.4
  • 11
    • 56349083606 scopus 로고    scopus 로고
    • Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis
    • Paintlia AS, Paintlia MK, Singh I, Singh AK. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008; 214:168-180.
    • (2008) Exp Neurol , vol.214 , pp. 168-180
    • Paintlia, A.S.1    Paintlia, M.K.2    Singh, I.3    Singh, A.K.4
  • 12
    • 46349098412 scopus 로고    scopus 로고
    • Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production
    • Lavrnja I, Stojkov D, Bjelobaba I, et al. Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. Int Immunopharmacol 2008; 8:1282-1290.
    • (2008) Int Immunopharmacol , vol.8 , pp. 1282-1290
    • Lavrnja, I.1    Stojkov, D.2    Bjelobaba, I.3
  • 13
    • 41549104613 scopus 로고    scopus 로고
    • Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity
    • Maassen CBM, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 2008; 26:2056-2057.
    • (2008) Vaccine , vol.26 , pp. 2056-2057
    • Maassen, C.B.M.1    Claassen, E.2
  • 14
    • 53049091541 scopus 로고    scopus 로고
    • Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encepha lomyelitis
    • Hassen GW, Feliberti J, Kesner L, et al. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encepha lomyelitis. Brain Res 2008; 1236:206-215.
    • (2008) Brain Res , vol.1236 , pp. 206-215
    • Hassen, G.W.1    Feliberti, J.2    Kesner, L.3
  • 15
    • 58149465736 scopus 로고    scopus 로고
    • Comparison of the immunomodulatory effects of the plant sterol ß-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients
    • Desai F, Ramanathan M, FinkCS, et al. Comparison of the immunomodulatory effects of the plant sterol ß-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int Immunopharmacol 2009; 9:153-157.
    • (2009) Int Immunopharmacol , vol.9 , pp. 153-157
    • Desai, F.1    Finkcs, R.M.2
  • 16
    • 48349088568 scopus 로고    scopus 로고
    • Reduction of free radicals in multiple sclerosis: Effect of glatiramer acetate (Copaxone®)
    • Iarlori C, Gambi D, Lugaresi A, et al. Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®). Mult Scler 2008; 14:739-748.
    • (2008) Mult Scler , vol.14 , pp. 739-748
    • Iarlori, C.1    Gambi, D.2    Lugaresi, A.3
  • 17
    • 68849084141 scopus 로고    scopus 로고
    • IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
    • Jones JL, Phuah C-L, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052-2061.
    • (2009) J Clin Invest , vol.119 , pp. 2052-2061
    • Jones, J.L.1    Phuah, C.-L.2    Cox, A.L.3
  • 18
    • 41849116363 scopus 로고    scopus 로고
    • Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, Phase i Trial
    • Baror A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I Trial. Ann Neurol 2008; 63:395-400.
    • (2008) Ann Neurol , vol.63 , pp. 395-400
    • Baror, A.1    Calabresi, P.A.J.2    Arnold, D.3
  • 19
    • 59349105358 scopus 로고    scopus 로고
    • The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relap sing-remitting multiple sclerosis
    • De Stefano N, Filippi M, Confavreux C, et al. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relap sing-remitting multiple sclerosis. Mult Scler 2009; 15:238-243.
    • (2009) Mult Scler , vol.15 , pp. 238-243
    • De Stefano, N.1    Filippi, M.2    Confavreux, C.3
  • 20
    • 63849147004 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
    • O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009; 72:73-79.
    • (2009) Neurology , vol.72 , pp. 73-79
    • O'Connor, P.1    Comi, G.2    Montalban, X.3
  • 21
    • 48849087125 scopus 로고    scopus 로고
    • Repeated subcuta neous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study
    • Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcuta neous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796-804.
    • (2008) Lancet Neurol , vol.7 , pp. 796-804
    • Segal, B.M.1    Constantinescu, C.S.2    Raychaudhuri, A.3
  • 22
    • 50549098795 scopus 로고    scopus 로고
    • Intravenous immunoglobulin in relapsingremitting multiple sclerosis: A dose-finding trial
    • Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsingremitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71:265-271.
    • (2008) Neurology , vol.71 , pp. 265-271
    • Fazekas, F.1    Lublin, F.D.2    Li, D.3
  • 23
    • 45249107267 scopus 로고    scopus 로고
    • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
    • (2008) Lancet , vol.371 , pp. 2085-2092
    • Comi, G.1    Pulizzi, A.2    Rovaris, M.3
  • 24
    • 44849103664 scopus 로고    scopus 로고
    • Phase 2 Trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
    • Garren H, Robinson WH MD, Krasulova E, et al. Phase 2 Trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008; 63:611-620.
    • (2008) Ann Neurol , vol.63 , pp. 611-620
    • Garren, H.1    Robinson Wh, M.D.2    Krasulova, E.3
  • 25
    • 54149116366 scopus 로고    scopus 로고
    • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, doubleblind, placebo-controlled phase IIb study
    • KapposL, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, doubleblind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
    • (2008) Lancet , vol.372 , pp. 1463-1472
    • Kapposl Gold, R.1    Miller, D.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.